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ABSTRACT 
INTRODUCTION: Parvovirus B19 (PVB19) is a DNA virus transmissible by blood transfusion. It is a major cause of aplastic 
crisis especially in chronic haemolytic anaemic patients such as sickle cell disease patients.  
OBJECTIVE: The study was aimed to determine the seroprevalence of PVB19 in blood donors and sickle cell anaemia (SCA) 
patients and to evaluate its association with blood transfusion in SCA patients. 
METHODS: This is a cross sectional study conducted at the Lagos University Teaching Hospital, Lagos Nigeria. Three hundred 
participants, consisting of 150 voluntary blood donors and 150 sickle cell anaemia subjects were enrolled into the study. 
Seroprevalence of parvovirus was determined using ELISA kits for IgG and IgM anti-PVB19 antibodies by Immuno-Biological 
Laboratories, (IBL) inc.  Minneapolis, USA. Results was analyzed with SPSS 11 software and presented in tables. Fishers Exact 
test, Chi-square and student T-test were used as appropriate to compare variables between both groups. P-values <0.05 were 
considered significant. 
RESULTS: Ninety nine (66%) blood donors were positive for anti-PVB19 IgG antibody while ninety two (61.3%) sickle cell 
patients were positive. Two (1.3%) blood donors were positive anti-PVB19 IgM antibodies while 8 (5.3%) SCD patients were 
positive for anti-PVB19 IgM antibodies. There was no significant difference in the seroprevalence of IgG and IgM antiPVB19 
virus in both groups. There was no association of parvovirus seroprevalence with blood transfusion.  
CONCLUSION: The study has shown a high seroprevalence of IgG anti-PVB19 antibodies in both blood donors and SCA 
patients. Therefore routine screening for parvovirus infection for donor blood is not justified. However seronegative SCA 
patients who require blood transfusion should have the blood screened for parvovirus to reduce the risk of associated aplastic 
crisis. 
Key words: Seroprevalence, parvovirus B19, blood donors, sickle cell anaemia 
 
INTRODUCTION 
Parvovirus B19 (PVB19) a DNA virus belonging to the 
parvoviridae family and erythrovirus genus (1). It is 
one of the transfusion transmissible viruses. Others 
include hepatitis B virus (HBV), hepatitis C virus 
(HCV), human immunodeficiency virus (HIV), 
human T cell leukaemia virus I (HTLV1), 
cytomegalovirus (CMV) and Epstein-Barr virus (EBV) 
(1).  
It is non-enveloped, with icosahedral nucleocapsid 
symmetry, and measures 22-24 nm in diameter. The 
virus has a linear nucleic acid (DNA) of ~5.6 kb in 
length. There are 3 genotypes 1, 2 and 3. Genotype 1 
is responsible for the majority of human infections 
worldwide; genotypes 2 and 3 appear to have some 
geographic and temporal variation in distribution. 
The virus is resistant to dry heat, freezing and lipid 
solvents. It is inactivated by formalin, β-propiolactone 
and gamma irradiation (1).  
The virus is transmitted mainly as droplet infections, 
vertically through placental to fetus and through 
blood transfusion. At risk population include 
children, pregnant women, immunocompromised 
and those with chronic haemolytic anemia such sickle 
cell and Thalassemia patients (1, 2). 
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Clinical manifestations range from asymptomatic 
disease in immunocompetent to symptomatic disease 
in the immunocompromised. Clinical features include 
erythema infectiosum (fifth disease) in children, 
arthropathy, aplastic anemia/crisis and fetal hydrops 
(1). 
Acute infection is associated with a viremic phase 
shortly followed by IgM antibody production (10 – 14 
days post-infection). This is followed by IgG antibody 
production against the viral capsid. Viraemia declines 
with IgM production; IgM declines after a few 
months but IgG persists longer to convey immunity 
against reinfection. Infrequently, low level PVB19 
nucleic acid may persist with IgG for months or years. 
Parvovirus B19 infection has been reported globally. 
Recent infection is associated with the secretion of 
immunoglobulin M (IgM) antibodies in plasma while 
IgG signify previous exposure.  
Anti-parvovirus IgG antibody seroprevalence rates 
are similar in the United States, Europe, and Asia (3 – 
5).                                                             
The virus has a direct cytopathic effect on erythroid 
progenitors in bone marrow leading to an arrest in 
the maturation and subsequent anaemia. The clinical 
manifestation varies widely depending on the 
immunological and haematological status of the host. 
In individuals with underlying haemolytic disorders, 
as in patients with sickle cell anaemia  (SCA), PVB19 
infection may cause transient erythroblastopenia 
(TEB), characterized by a fall in haemoglobin level 
with reticulocytopaenia (6). Other manifestations of 
parvovirus infection include arthritis, vasculitis, 
myocarditis, liver failure and fetal loss. 
Sickle cell anaemia is one of the most prevalent 
genetic diseases in Nigeria (7). SCA patients have 
accelerated premature haemolysis with significant 
reduction in red cell half life. Generally, the chronic 
haemolysis and resulting anaemia is well tolerated 
however, a reduction in the level of haemoglobin 
below the steady state may be detrimental to the 
patient; necessitating blood transfusion (8, 9). 
Transfusion may predispose them to increased risk of 
immunological and infectious complications. 
Accurate epidemiologic data on the frequency of 
Parvovirus B19 infection in patient with sickle cell 
anaemia are essential for assessing the potential effect 
of viral prevention programs in this patient 
population (10). However there are limited data on 
the seroprevalence of PVB19 infection in our 
environment hence the justification for this study. 
The findings from this work may justify need for 
routine parvovirus B19 screening of blood products 
before transfusing sickle cell patients or justify the 
need for institution of vaccination program SCA 
patients.  
OBJECTIVES 
The study was aimed at determining the 
seroprevalence of parvovirus B19 antibodies (IgG and 
IgM) among SCA patients and blood donors; to 
compare the seroprevalence rates between both 
groups and to determine its association with blood 
transfusion.    
METHODOLOGY       
Study design: This was a cross sectional study 
conducted at the Lagos University Teaching Hospital, 
Idi-Araba. 
Sample size: This was calculated using the Kirkwood 
formula for cross sectional study. An estimated 
prevalence rate of 50% was used. A total of 300 
subjects were recruited for the study. 
Study participants: There are 2 study groups. Group 
1 comprises 150 voluntary blood donors recruited 
from the donor clinic. Group 2 comprises 150 SCA 
patients attending clinic at the Sickle Cell Centre in 
LUTH. A structured questionnaire was used to obtain 
personal and medical data from the subjects and 
venous blood was collected for serological and 
haematological analysis. 
Ethical Considerations: The study was approved by 
the ethical committee of the hospital. An informed 
consent was given by all participants above 18 years 
while consent was obtained from guardians for 
patients below 18 years in the language best 
understood by them. 
Inclusion and Exclusion Criteria 
Inclusion criteria for blood donors: Age between 18-
60 years; Weight >50 kg; Hb >12.5g/dl; Normal blood 
pressure, pulse, and temperature. 
Exclusion criteria for blood donors: History of 
chronic illness e.g. Hypertension, Diabetes, Asthma; 
commercial sex workers and Intravenous drug users.  
Inclusion criteria for sickle cell patients include SCA 
aged 5 years and above. 
Sample Collection: Ten milliliters (mls) of venous 
blood was collected from the antecubital fossa using 
aseptic technique. Five mls was dispensed into a 
sterile plain bottle and allowed to stand at room 
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temperature until clotted. The samples was 
centrifuged, serum separated into another sterile 
bottle stored at -20oC until the required sample size 
were obtained. 
The other 5mls was dispensed into EDTA bottle for 
full blood count, reticulocyte count and red cell 
indices. Samples were analyzed within 2 hours of 
collection using automated haematology analyzer. 
The reticulocyte count was performed manually as 
described in Decie and Lewis (11). 
Parvovirus B19 IgG and IgM Assays 
IgG and IgM assay were determined using a solid 
phase enzyme – linked immunosorbent assay (ELISA) 
kits for IgG and IgM anti-PVB19 antibodies by 
Immuno-Biological Laboratories, (IBL) inc.  
Minneapolis, USA.  
Assay Procedure  
The required number of microtitre strips or wells 
were selected and inserted into the holder. Wells were 
filled with 300µL of diluted wash solution and 
allowed to soak for 5 minutes and aspirated off. 
Sample was dispensed into each properly identified 
well using the work sheet as a guide. 100 µL each of 
negative control, cut-off control, positive control, 
diluted samples were dispensed into appropriate 
wells and a microwell was left for substrate blank. 
Wells were covered with foil and incubated for 60 
minutes at room temperature. 
The contents of the wells were briskly shaked out and 
rinsed five times with diluted wash solution and then 
strike on absorbent paper to remove residual 
droplets. 
100µL of enzyme conjugate was dispensed into each 
well except the blank. All the wells were covered with 
foil and incubated for 30 minutes at room 
temperature. The contents of the wells were briskly 
shake out and rinsed five times with diluted wash 
solution and then strike on absorbent paper to 
remove residual droplets. 
100 µL of substrate solution was added into all wells. 
Wells were covered with foil and incubated for 
exactly 15 minutes at room temperature. Enzymatic 
reaction was stopped by adding 100µL of stopped 
solution to each well. There is a colour change from 
blue to yellow. The intensity of the colour is 
proportional to the antibody titre. 
Optical density was read at 450nm blanking the 
instrument with the blank microwell. 
Results were interpreted according to manufacturer’s 
instructions. 
Internal Quality Control Measures 
Negative, cut-off, positive controls and blanks were 
used in each run.  
For IgM assay, patient serum samples are diluted and 
simultaneously absorbed with sample diluents 
containing hyper immune anti-IgG-class antibody to 
eliminate competitive inhibition from specific IgG 
and to remove rheumatoid factor. 
Statistical analysis 
The results were analyzed using statistical package 
for social science (SPSS 11.0), and Epi-info 6.0. The 
results were presented with in frequency tables. 
Comparism of the seroprevalence of IgG and IgM 
anti-PBV19 antibodies in both groups was made 
using chi-square and Fishers Exact test as 
appropriate. Other numerical parameters were 
compared using the student T-test. The association of 
anti- PVB19 antibody with blood transfusion was 
determined using odd ratio. Significance level was set 
at p< 0.05. 
 RESULTS 
Demographic parameters of the subjects 
A total of 300 subjects were studied consisting of 150 
sickle cell patients and 150 blood donors. Their mean 
ages (in years) were 20.29 ± 11.27 and 30.43 ± 9.58 for 
the sickle cell subjects and blood donors respectively. 
The SCA subjects included 70 (46.7%) females and 80 
(53.3%) males while blood donors included 6 (4%) 
females and 144 (94%) males. Tables 1and 2 show the 








TABLE 1: SHOWS THE MEAN AGE, SEX, SEROPREVALENCE AND HAEMATOLOGICAL PARAMETERS OF                               
THE STUDY SUBJECTS 
Variables  Blood Donors  
(N = 150) 
SCA 
(N = 150) 
P values 











Positive history of Blood Transfusion 13 (8.67%) 76 (50.67%)  
Seroprevalence of PVB19    
IgG 99 (66.0%) 92 (61.3%) 0.47 
IgM 2 (1.3%) 8 (5.3%) 0.11 
IgM and IgG 1 (0.67%) 4 (2.67%)  
    
Haematological Parameters    
WBC/mm3 9.85 ± 3.87 4.28 ± 1.01 <0.01 
Neut/mm3 5.16 ± 2.48 2.13 ± 0.80 <0.01 
Lymph/mm3 3.84 ±1.68 1.81 ± 0.51 <0.01 
Platelet x 109/l 355 ± 150 227 ± 168 <0.01 
Hb (g/dl) 7.51 ± 1.62 13.72 ± 1.54 <0.01 
Reticulocyte (%) 5.30 ± 2.43 1.22 ± 0.47 <0.01 
MCV (fl) 81.53 ± 5.54 84.24 ± 10.35 <0.01 
MCHC (g/dl) 32.51 ± 13.66 32.15 ± 12.40 0.02 
MCH (pg) 26.88 ± 3.22 27.22 ± 2.77 0.33 
    
 
TABLE2: AGE AND SEX DISTRIBUTION OF THE STUDY SUBJECTS 
Age (Yrs) SCA 
(N = 150) 
Blood donors 
(N = 150) 
 Female Male Female Male 
< 11 9 24 0 0 
11 – 17 19 15 0 0 
18 – 24 19 22 2 47 
25 – 31 8 6 3 46 
32 – 38 8 6 0 20 
39 – 45 4 6 0 21 
46 – 52 3 1 0 6 
>52 0 0 1 4 
Total 70 80 6 144 
 
History of blood transfusion                              
Seventy six (50.67%) of the Sickle cell patients had a 
history of previous blood transfusion while 13 (8.67%) 
of the blood donors had been transfused in the past. 
Seroprevalence of parvovirus antibodies in the 
participants                                                                                
A total of 92 (61.3%) sickle cell patients were anti-
PVB19 positive and 99 (66.0%) of the blood donors 
were also positive for IgG. For IgM anti-PVB19, 8 
(5.3%) sickle cell anaemia patients were positive while 
2 (1.3%) of the blood donors were positive. There was 
no significant difference in the prevalence of IgG and 
IgM anti-PVB19 antibodies between both group (P = 
0.471 and 0.1078 respectively). Four of the sickle cell 
anaemic patients were positive for both IgG and IGM 
anti-PVB19 antibodies while only one of the healthy 
donors was positive for both antibodies as shown in 
Table 1. 
The seroprevalence by age and sex are presented in 
Tables 3 and 4. Tables 5 and 6 represent its association 
with blood transfusion in the study subjects. 
Haematological parameters                                                   
The haematological parameters of the participants are 
as presented in Table 1. Table 7 compares 
haematological parameters in SCA subjects with IgG 
and IgM antibodies. Reticulocyte counts were 
significantly reduced in SCA subjects with IgM 
antibodies. 
DISCUSSION                                                       
Parvovirus B19 is one of the emerging transfusion 
transmissible infections. It has been widely studied in 
various countries among healthy blood donors and 
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sickle cell patients with results indicating a high 
seroprevalence of the virus in the study areas 
however there are limited publications on parvovirus 
in SCA patients and blood donors in our 
environment. In this study, we found a 
seroprevalence rate of 66% for IgG antibody in 
healthy blood donors. 
Abraham et al and Munoz et al reported 
seroprevalence of 65% each for IgG antibody in blood 
donors in India (12) and Salamanca, Spain (13) 
respectively. In various studies in developed nations, 
rates between 55 – 77% were reported (3 – 5). The 
seroprevalence rates from these studies were 
comparably the same with our findings. However, 
Mata et al reported a low seroprevalence of 9.8% 
(anti-IgG) in a cross sectional study conducted among 
92 blood donors in Galicia in Spain (14). This is 
significantly lower than what we found in our study. 
This shows that there are geographical variations in 
the seroprevalence of parvovirus infection. 
TABLE3: SEROPREVALENCE OF IGG AND IGM ANTIBODIES BY AGE IN SCA PATIENTS AND BLOOD DONORS 








< 11 18 0 0 0 
11 – 17 20 0 0 0 
18 – 24 28 33 2 47 
25 – 31 10 31 3 46 
32 – 38 6 14 0 20 
39 – 45 7 16 0 21 
46 – 52 3 1 0 6 
>52 0 4 1 4 
Total 92 99 6 144 
 
TABLE 4: ASSOCIATION OF IGG PARVOVIRUS ANTIBODIES WITH SEX IN SCA PATIENTS AND BLOOD DONORS 
Sex  SCA IgG status Blood donors IgG status 
 Negative Positive Total Negative Positive Total 
Female 22 48 70 1 5 6 
Male 36 44 80 50 94 144 
Total 58 92 150 51 99 150 
P-value 0.089 0.360 
 
TABLE 5: ASSOCIATION OF IGG PARVOVIRUS ANTIBODIES WITH BLOOD TRANSFUSION IN SCA PATIENTS AND 
IN BLOOD DONORS 
Transfusion Status SCA IgG status Blood donors IgG status 
 Positive Negative Total Positive Negative Total 
Transfused 44 32 76 6 7 13 
Not transfused 48 26 74 93 44 137 
Total 92 58 150 99 51 150 
 P-value = 0.4785 P-value 0.2026 
 
TABLE 6: ASSOCIATION OF IGM PARVOVIRUS ANTIBODIES WITH BLOOD TRANSFUSION IN SCA PATIENTS AND 
IN BLOOD DONORS 
Transfusion Status SCA IgM status Blood donors IgM status 
 Positive Negative Total Positive Negative Total 
Transfused 1 75 76 0 13 13 
Not transfused 7 67 74 2 135 137 
Total 8 142 150 2 148 150 
 P-value = 0.0635 P-value 0.4085 
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The seroprevalence of Parvovirus B19 IgG antibody in 
SCA patients was found to be 61.3% in this study. Ujo 
et al (15) in a cross sectional study in paediatric SCA 
patients in Zaria found a seroprevalence rate of 
85.4%.  
The study also found that there is no sex association 
in the seroprevalence of the virus in both SCA 
patients and healthy blood donors. This is in 
agreement with the findings of Ujo et al (15) and 
Teuscher et al (16) in their separate studies.  
This study also found that though blood donors have 
a slightly higher seroprevalence than SCA patients, 
this was not statistically significant. Teuscher et al (16) 
and Serjeant et al (6) in their separate studies also 
found no significant difference in the seroprevalence 
of the virus in both study groups. This suggest that 
SCA patients are not at increased risk when 
compared to the general populace however due to the 
fact that they have a lower stable haemoglobin value, 
parvovirus infection in them may result in 
symptomatic anaemia necessitating transfusion. 
TABLE 7: COMPARISM OF HAEMATOLOGICAL PARAMETERS IN SCA PATIENTS WITH IGG AND IGM PARVOVIRUS 
ANTIBODIES 
Haematological Parameters IgG 
Mean ± SD 
N = 92 
IgM 
Mean ± SD 
N = 8 
P value 
WBC x 109 9.93 ± 4.29 9.81 ± 3.80 0.94 
Neutrophils x 109 5.25 ± 2.72 4.58 ± 1.80 0.49 
Lymphocytes x 109 3.90 ± 1.93 4.40 ± 2.11 0.49 
Platelets x 109 348.66 ± 149.69 293.63 ± 176.96 0.33 
Hb (g/dl) 9.46 ± 1.57 7.15 ± 1.97 0.60 
Reticulocyte (%) 5.48 ± 2.42 1.19 ± 0.59 <0.01 
MCV (fl) 82.30 ± 8.33 80.18 ± 9.35 0.50 
MCH (pg) 27.11 ± 3.37 26.29 ± 3.36 0.51 
MCHC (g/dl) 32.64 ± 1.31 32.74 ± 0.89 0.83 
 
Studies have shown that by 15 years of age, about 
50% of some populace are positive for PVB19 IgG 
antibodies (1, 17, 18). Some studies have noted an 
increase in seroprevalence of the virus with age.18 
Kim et al in their study on the epidemiology of 
parvovirus in sickle cell disease patients reported an 
increase in seroprevalence with age (19).In this study, 
we found a peak age prevalence to be 18 – 24 years in 
SCA patients and blood donors. This is higher than 
that reported by Ujo et al (15).  
The seroprevalence of parvovirus B19 IgM antibody 
in sickle cell anaemia subjects and blood donors were 
found to be 5.3% and 1.3% respectively. Doyle and his 
coworker found seroprevalence of 1% prevalence 
among American blood donors (4) while Munoza 
reported 0% in Spanish blood donors (20). The 
seroprevalence of PVB 19 may vary with the 
sensitivity of the test used in addition to geographical 
and seasonal variations. The possibility of 
transmission of PVB19 by blood and blood products 
raises several blood safety questions still unanswered 
(21 – 23). Human blood and its components are 
widely used as life saving therapy in hospital 
practices. However, there is an associated risk of 
transmission of infections such as HIV, hepatitis and 
parvovirus inclusive due to infected donor blood (23). 
Parvovirus lacking a lipid envelope is not susceptible 
to the solvent-detergent treatment which can 
inactivate pathogens with envelopes such as HIV, 
hepatitis B and C among others transmissible by 
blood. The virus is stable in heat and remains 
infective even after treatment with dry heat at 80°C 
for 72 hours, which was used for treating some blood 
products. Hence the reports on a high prevalence of 
PVB19 in haemophilic patients receiving pooled 
blood products (24, 25). In non-immune sickle cell 
anaemia patients, the clinical manifestation of the 
virus upon infection may include transient aplastic 
crisis, which is indicated by a fall in haemoglobin 
with reticulocytopaenia.  Serjeant et al in their study 
of epidemiology of human parvovirus B19 infection 
in Jamaica in homozygous sickle cell disease found 
that PVB19 infection account for most if not all 
aplastic crisis in SS disease (6). 
The lack of a statistically significant difference 
between the seroprevalence of PVB19 antibodies 
between blood donors and SCA patients will suggest 
that blood transfusion may not the major means of 
transmission of parvovirus SCA patients. This finding 
highlights the importance of investigating other 
means of transmission other than blood transfusion as 
recommended in the report of the Committee on 
Infectious Diseases (17). The reticulocyte percentages 
of IgG antibody positive SCA patients are generally 
higher than that of IgM positive SCA subjects. This 
affirms the risk of transient aplasia associated with 
acute or persistent parvovirus infection documented 
in some previous studies (19). This is understandable 
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in the light of the cytopathic effect of PVB19 on 
haemopoietic precursor cells in the bone marrow. In 
conclusion, this study has shown a high 
seroprevalence of IgG anti-PVB19 antibodies in sickle 
cell patients and voluntary blood donors in our 
environment. This suggests that it may not be cost 
effective to recommend routine donor screening for 
PVB19 antibodies. However, because of the increased 
risk of aplastic crisis in SCA patients, SCA patients 
who require transfusion and are seronegative for 
PVB19 should have the blood screened for PBV virus. 
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